UA66339C2 - Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування - Google Patents

Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування Download PDF

Info

Publication number: UA66339C2
Authority: UA; Ukraine
Prior art keywords: truncated; protein; sequence; zeo; zome
Prior art date: 1995-09-28

Application number

UA98031545A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Шоу-Фен Ху

Original Assignee

Амген Інк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-28

Filing date

1996-09-16

Publication date

2004-05-17

1996-09-16 Application filed by Амген Інк. filed Critical Амген Інк.

2004-05-17 Publication of UA66339C2 publication Critical patent/UA66339C2/uk

Links

210000004027 cell Anatomy 0.000 title claims description 131
108020004414 DNA Proteins 0.000 title claims description 79
238000000034 method Methods 0.000 title claims description 77
239000013598 vector Substances 0.000 title claims description 47
108010025020 Nerve Growth Factor Proteins 0.000 title claims description 27
102000007072 Nerve Growth Factors Human genes 0.000 title claims description 26
239000003900 neurotrophic factor Substances 0.000 title claims description 26
238000011282 treatment Methods 0.000 title claims description 25
102000053602 DNA Human genes 0.000 title claims description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 10
210000004498 neuroglial cell Anatomy 0.000 title claims description 3
238000002360 preparation method Methods 0.000 title abstract description 17
101150082979 gdnf gene Proteins 0.000 title 3
108090000765 processed proteins & peptides Proteins 0.000 claims description 68
230000014509 gene expression Effects 0.000 claims description 51
125000003275 alpha amino acid group Chemical group 0.000 claims description 40
229920001184 polypeptide Polymers 0.000 claims description 36
102000004196 processed proteins & peptides Human genes 0.000 claims description 36
125000000539 amino acid group Chemical group 0.000 claims description 34
210000005064 dopaminergic neuron Anatomy 0.000 claims description 33
238000004519 manufacturing process Methods 0.000 claims description 33
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 18
208000018737 Parkinson disease Diseases 0.000 claims description 13
230000001580 bacterial effect Effects 0.000 claims description 13
229920003169 water-soluble polymer Polymers 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 12
230000006378 damage Effects 0.000 claims description 10
125000003277 amino group Chemical group 0.000 claims description 9
208000035475 disorder Diseases 0.000 claims description 9
230000000508 neurotrophic effect Effects 0.000 claims description 9
210000004962 mammalian cell Anatomy 0.000 claims description 8
208000014674 injury Diseases 0.000 claims description 7
235000015097 nutrients Nutrition 0.000 claims description 7
208000027418 Wounds and injury Diseases 0.000 claims description 6
210000000653 nervous system Anatomy 0.000 claims description 6
238000003776 cleavage reaction Methods 0.000 claims description 5
238000003259 recombinant expression Methods 0.000 claims description 5
230000007017 scission Effects 0.000 claims description 5
244000068988 Glycine max Species 0.000 claims description 4
235000010469 Glycine max Nutrition 0.000 claims description 4
238000012258 culturing Methods 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
108091029865 Exogenous DNA Proteins 0.000 claims 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract description 37
241000701161 unidentified adenovirus Species 0.000 abstract description 5
208000012902 Nervous system disease Diseases 0.000 abstract description 3
208000025966 Neurological disease Diseases 0.000 abstract description 2
230000003412 degenerative effect Effects 0.000 abstract description 2
102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 abstract 2
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 description 441
102000004169 proteins and genes Human genes 0.000 description 403
235000018102 proteins Nutrition 0.000 description 399
150000001413 amino acids Chemical class 0.000 description 108
235000001014 amino acid Nutrition 0.000 description 102
229940024606 amino acid Drugs 0.000 description 100
239000000047 product Substances 0.000 description 69
150000007523 nucleic acids Chemical group 0.000 description 53
229920000642 polymer Polymers 0.000 description 40
210000002569 neuron Anatomy 0.000 description 37
229920001223 polyethylene glycol Polymers 0.000 description 37
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 34
239000002609 medium Substances 0.000 description 28
239000000203 mixture Substances 0.000 description 27
239000000243 solution Substances 0.000 description 27
239000000872 buffer Substances 0.000 description 26
108091033319 polynucleotide Proteins 0.000 description 25
102000040430 polynucleotide Human genes 0.000 description 25
239000002157 polynucleotide Substances 0.000 description 25
238000006467 substitution reaction Methods 0.000 description 23
230000000694 effects Effects 0.000 description 22
238000006243 chemical reaction Methods 0.000 description 21
238000012217 deletion Methods 0.000 description 21
230000037430 deletion Effects 0.000 description 21
239000000523 sample Substances 0.000 description 21
239000002299 complementary DNA Substances 0.000 description 20
241000894007 species Species 0.000 description 19
238000010521 absorption reaction Methods 0.000 description 18
229960003638 dopamine Drugs 0.000 description 18
230000008569 process Effects 0.000 description 18
239000000463 material Substances 0.000 description 17
210000003523 substantia nigra Anatomy 0.000 description 16
108010076504 Protein Sorting Signals Proteins 0.000 description 15
238000007792 addition Methods 0.000 description 15
230000013595 glycosylation Effects 0.000 description 15
238000006206 glycosylation reaction Methods 0.000 description 15
210000001519 tissue Anatomy 0.000 description 15
239000013612 plasmid Substances 0.000 description 14
239000002202 Polyethylene glycol Substances 0.000 description 13
239000003636 conditioned culture medium Substances 0.000 description 13
230000028436 dopamine uptake Effects 0.000 description 13
238000009396 hybridization Methods 0.000 description 13
240000004808 Saccharomyces cerevisiae Species 0.000 description 12
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
239000003814 drug Substances 0.000 description 12
239000001963 growth medium Substances 0.000 description 12
230000006320 pegylation Effects 0.000 description 12
230000003321 amplification Effects 0.000 description 11
238000010367 cloning Methods 0.000 description 11
230000000875 corresponding effect Effects 0.000 description 11
229940079593 drug Drugs 0.000 description 11
239000013604 expression vector Substances 0.000 description 11
239000012634 fragment Substances 0.000 description 11
238000003780 insertion Methods 0.000 description 11
230000037431 insertion Effects 0.000 description 11
230000035772 mutation Effects 0.000 description 11
238000003199 nucleic acid amplification method Methods 0.000 description 11
238000012216 screening Methods 0.000 description 11
210000004556 brain Anatomy 0.000 description 10
239000003623 enhancer Substances 0.000 description 10
238000000746 purification Methods 0.000 description 10
239000000126 substance Substances 0.000 description 10
238000013518 transcription Methods 0.000 description 10
230000035897 transcription Effects 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 9
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
238000001212 derivatisation Methods 0.000 description 9
102000039446 nucleic acids Human genes 0.000 description 9
108020004707 nucleic acids Proteins 0.000 description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
239000013615 primer Substances 0.000 description 9
238000005932 reductive alkylation reaction Methods 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
238000005406 washing Methods 0.000 description 9
108010022394 Threonine synthase Proteins 0.000 description 8
238000005917 acylation reaction Methods 0.000 description 8
230000007850 degeneration Effects 0.000 description 8
102000004419 dihydrofolate reductase Human genes 0.000 description 8
239000000499 gel Substances 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
239000011347 resin Substances 0.000 description 8
229920005989 resin Polymers 0.000 description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
241000700159 Rattus Species 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
230000007423 decrease Effects 0.000 description 7
230000002950 deficient Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000010076 replication Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 6
230000010933 acylation Effects 0.000 description 6
238000005804 alkylation reaction Methods 0.000 description 6
-1 amino- Chemical class 0.000 description 6
239000002585 base Substances 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000027455 binding Effects 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
239000000539 dimer Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
239000008103 glucose Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
239000000178 monomer Substances 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
238000012545 processing Methods 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
238000001262 western blot Methods 0.000 description 6
108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
241000700605 Viruses Species 0.000 description 5
150000001299 aldehydes Chemical class 0.000 description 5
230000029936 alkylation Effects 0.000 description 5
238000004166 bioassay Methods 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
230000008859 change Effects 0.000 description 5
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
210000003000 inclusion body Anatomy 0.000 description 5
238000001802 infusion Methods 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
239000002751 oligonucleotide probe Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000008685 targeting Effects 0.000 description 5
238000001890 transfection Methods 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
108020005187 Oligonucleotide Probes Proteins 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
239000004365 Protease Substances 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000006240 deamidation Effects 0.000 description 4
230000029087 digestion Effects 0.000 description 4
230000003291 dopaminomimetic effect Effects 0.000 description 4
210000002257 embryonic structure Anatomy 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000710 homodimer Substances 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
235000013336 milk Nutrition 0.000 description 4
239000008267 milk Substances 0.000 description 4
210000004080 milk Anatomy 0.000 description 4
210000001577 neostriatum Anatomy 0.000 description 4
230000001537 neural effect Effects 0.000 description 4
210000002241 neurite Anatomy 0.000 description 4
229940049954 penicillin Drugs 0.000 description 4
239000002243 precursor Substances 0.000 description 4
239000002987 primer (paints) Substances 0.000 description 4
230000002797 proteolythic effect Effects 0.000 description 4
239000002904 solvent Substances 0.000 description 4
230000003595 spectral effect Effects 0.000 description 4
238000003860 storage Methods 0.000 description 4
229960005322 streptomycin Drugs 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000012546 transfer Methods 0.000 description 4
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
241000699802 Cricetulus griseus Species 0.000 description 3
102000016911 Deoxyribonucleases Human genes 0.000 description 3
108010053770 Deoxyribonucleases Proteins 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
102400001368 Epidermal growth factor Human genes 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
108010058846 Ovalbumin Proteins 0.000 description 3
108090000526 Papain Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108090000901 Transferrin Proteins 0.000 description 3
102000004338 Transferrin Human genes 0.000 description 3
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
239000008351 acetate buffer Substances 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
235000009582 asparagine Nutrition 0.000 description 3
229960001230 asparagine Drugs 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
239000012888 bovine serum Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000004087 circulation Effects 0.000 description 3
230000001143 conditioned effect Effects 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
230000034994 death Effects 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000001647 drug administration Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 3
238000012744 immunostaining Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000011068 loading method Methods 0.000 description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
229960000485 methotrexate Drugs 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
230000002474 noradrenergic effect Effects 0.000 description 3
229960003104 ornithine Drugs 0.000 description 3
229940092253 ovalbumin Drugs 0.000 description 3
235000019834 papain Nutrition 0.000 description 3
229940055729 papain Drugs 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000035515 penetration Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000006152 selective media Substances 0.000 description 3
239000012581 transferrin Substances 0.000 description 3
230000010474 transient expression Effects 0.000 description 3
230000032258 transport Effects 0.000 description 3
229910052722 tritium Inorganic materials 0.000 description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000233866 Fungi Species 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
241000170545 Iago Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 2
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
108010006232 Neuraminidase Proteins 0.000 description 2
102000005348 Neuraminidase Human genes 0.000 description 2
102100033857 Neurotrophin-4 Human genes 0.000 description 2
108090000099 Neurotrophin-4 Proteins 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
239000005864 Sulphur Substances 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000005056 cell body Anatomy 0.000 description 2
238000002659 cell therapy Methods 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
108010018927 conglutinin Proteins 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
230000022811 deglycosylation Effects 0.000 description 2
QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000002224 dissection Methods 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
108010085617 glycopeptide alpha-N-acetylgalactosaminidase Proteins 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
210000004201 immune sera Anatomy 0.000 description 2
229940042743 immune sera Drugs 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
210000001259 mesencephalon Anatomy 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
108010055896 polyornithine Proteins 0.000 description 2
229920002714 polyornithine Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
229960000856 protein c Drugs 0.000 description 2
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
101150024950 sstT gene Proteins 0.000 description 2
238000003756 stirring Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
REAWNMHCBIUKLZ-ZYHUDNBSSA-N (3R,4R)-4-(hydroxymethyl)-3-(6-methylheptanoyl)oxolan-2-one Chemical compound CC(C)CCCCC(=O)[C@H]1[C@H](CO)COC1=O REAWNMHCBIUKLZ-ZYHUDNBSSA-N 0.000 description 1
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
PYVRVRFVLRNJLY-KTKRTIGZSA-N 1-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COP(O)(=O)OCCN PYVRVRFVLRNJLY-KTKRTIGZSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000032484 Accidental exposure to product Diseases 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102100023635 Alpha-fetoprotein Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
241000713842 Avian sarcoma virus Species 0.000 description 1
102000040350 B family Human genes 0.000 description 1
108091072128 B family Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
108090000056 Complement factor B Proteins 0.000 description 1
102000003712 Complement factor B Human genes 0.000 description 1
108010026206 Conalbumin Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
101100256026 Drosophila melanogaster meigo gene Proteins 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
102000003967 Fibroblast growth factor 5 Human genes 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 description 1
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001190694 Muda Species 0.000 description 1
101100496087 Mus musculus Clec12a gene Proteins 0.000 description 1
101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000002740 Muscle Rigidity Diseases 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
102000004230 Neurotrophin 3 Human genes 0.000 description 1
108090000742 Neurotrophin 3 Proteins 0.000 description 1
108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
241000219492 Quercus Species 0.000 description 1
102000015097 RNA Splicing Factors Human genes 0.000 description 1
108010039259 RNA Splicing Factors Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
239000012891 Ringer solution Substances 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
229940125377 Selective β-Amyloid-Lowering Agent Drugs 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102100033929 Sodium-dependent noradrenaline transporter Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
235000018087 Spondias lutea Nutrition 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
231100000818 accidental exposure Toxicity 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
108020000715 acetylcholine receptors Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
VDTVZBCTOQDZSH-UHFFFAOYSA-N borane N-ethylethanamine Chemical compound B.CCNCC VDTVZBCTOQDZSH-UHFFFAOYSA-N 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
VEWFZHAHZPVQES-UHFFFAOYSA-N boron;n,n-diethylethanamine Chemical compound [B].CCN(CC)CC VEWFZHAHZPVQES-UHFFFAOYSA-N 0.000 description 1
NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006059 cover glass Substances 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
229920006176 crosslinked polyethyleneglycol Polymers 0.000 description 1
DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000002825 dopamine reuptake Effects 0.000 description 1
239000000221 dopamine uptake inhibitor Substances 0.000 description 1
210000004002 dopaminergic cell Anatomy 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000003325 follicular Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
108060003196 globin Proteins 0.000 description 1
102000018146 globin Human genes 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
108010026195 glycanase Proteins 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000000749 insecticidal effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000012976 mRNA stabilization Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000021121 meiosis Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
229960000554 metrizamide Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
HOEFWOBLOGZQIQ-UHFFFAOYSA-N morpholin-4-yl morpholine-4-carbodithioate Chemical compound C1COCCN1C(=S)SN1CCOCC1 HOEFWOBLOGZQIQ-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
229940032018 neurotrophin 3 Drugs 0.000 description 1
229940097998 neurotrophin 4 Drugs 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
229960001779 pargyline Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000001935 peptisation Methods 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
108010054442 polyalanine Proteins 0.000 description 1
230000003234 polygenic effect Effects 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
235000008001 rakum palm Nutrition 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000005185 salting out Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
229960001471 sodium selenite Drugs 0.000 description 1
235000015921 sodium selenite Nutrition 0.000 description 1
239000011781 sodium selenite Substances 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002330 subarachnoid space Anatomy 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229940124788 therapeutic inhibitor Drugs 0.000 description 1
239000012749 thinning agent Substances 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
230000006032 tissue transformation Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
229930195727 α-lactose Natural products 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

UA98031545A 1995-09-28 1996-09-16 Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування UA66339C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/535,681 US6184200B1 (en)	1995-09-28	1995-09-28	Truncated glial cell line-derived neurotrophic factor
PCT/US1996/014915 WO1997011964A1 (en)	1995-09-28	1996-09-16	Truncated glial cell line-derived neurotrophic factor

Publications (1)

Publication Number	Publication Date
UA66339C2 true UA66339C2 (uk)	2004-05-17

Family

ID=24135310

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA98031545A UA66339C2 (uk)	1995-09-28	1996-09-16	Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування

Country Status (25)

Country	Link
US (5)	US6184200B1 (ko)
EP (1)	EP0920448B1 (ko)
JP (3)	JP4153036B2 (ko)
KR (1)	KR100334739B1 (ko)
CN (1)	CN1283659C (ko)
AT (1)	ATE314389T1 (ko)
AU (1)	AU707528B2 (ko)
CA (1)	CA2232749C (ko)
CZ (1)	CZ297326B6 (ko)
DE (1)	DE69635675T2 (ko)
DK (1)	DK0920448T3 (ko)
EA (1)	EA001204B1 (ko)
ES (1)	ES2255713T3 (ko)
HK (1)	HK1021823A1 (ko)
HU (1)	HU226220B1 (ko)
IL (6)	IL123761A (ko)
MX (1)	MX9802278A (ko)
NO (1)	NO322521B1 (ko)
NZ (1)	NZ318697A (ko)
SI (1)	SI0920448T1 (ko)
SK (1)	SK288094B6 (ko)
TW (1)	TW570926B (ko)
UA (1)	UA66339C2 (ko)
WO (1)	WO1997011964A1 (ko)
ZA (1)	ZA968087B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6184200B1 (en) *	1995-09-28	2001-02-06	Amgen Inc.	Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en)	1996-05-08	2004-01-13	Biogen, Inc.	Ret ligand (RetL) for stimulating neutral and renal growth
DE19816186A1 (de) *	1998-04-14	1999-10-21	Univ Muenchen L Maximilians	GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US20020055467A1 (en) *	1998-07-06	2002-05-09	Johansen Teit E.	Novel neurotrophic factors
US6507788B1 (en) *	1999-02-25	2003-01-14	Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)	Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
US6897061B1 (en) *	2000-06-16	2005-05-24	Spinal Cord Society	Transdifferentiation of glial cells
US7442370B2 (en)	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
US7276580B2 (en)	2001-03-12	2007-10-02	Biogen Idec Ma Inc.	Neurotrophic factors
US8946151B2 (en) *	2003-02-24	2015-02-03	Northern Bristol N.H.S. Trust Frenchay Hospital	Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7245117B1 (en)	2004-11-01	2007-07-17	Cardiomems, Inc.	Communicating with implanted wireless sensor
EP1677833B1 (en)	2003-10-20	2010-03-10	Nsgene A/S	Virus vector for use in in vivo gene therapy of Parkinson's disease
CN1897977A (zh) *	2003-10-20	2007-01-17	Ns基因公司	帕金森氏病的体内基因治疗
ATE472333T1 (de)	2004-08-19	2010-07-15	Biogen Idec Inc	Rückfaltung von proteinen der transforming-growth-factor-beta-familie
TWI501774B (zh)	2006-02-27	2015-10-01	Biogen Idec Inc	神經性病症之治療
CN105820231A (zh) *	2006-08-04	2016-08-03	普罗龙药品有限责任公司	修饰型促红细胞生成素
US20090069230A1 (en) *	2007-02-12	2009-03-12	The Research Foundation Of State University Of New York	Gdnf-derived peptides
US8329655B2 (en)	2007-05-01	2012-12-11	Biogen Idec Ma Inc.	Methods for increasing vascularization
US8446454B2 (en)	2007-05-21	2013-05-21	Polycom, Inc.	Dynamic adaption of a continuous presence videoconferencing layout based on video content
FI20070808A0 (fi)	2007-10-25	2007-10-25	Mart Saarma	GDNF:n silmukointivariantit ja niiden käytöt
UA112981C2 (uk) *	2011-04-11	2016-11-25	Елі Ліллі Енд Компані	Варіант людського gdnf
US10376562B2 (en)	2013-03-15	2019-08-13	The Jackson Laboratory	Methods for promoting wound healing and hair growth comprising GDNF administration
RU2561050C2 (ru)	2013-08-28	2015-08-20	Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН)	Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
CN110461880A (zh)	2016-11-10	2019-11-15	科乐斯疗法公司	Gdnf融合多肽及其使用方法
CA3162011A1 (en) *	2019-12-19	2021-06-24	Rodolphe SORET	Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
KR20240110849A (ko)	2021-11-29	2024-07-16	상하이 레제네리드 테라피즈 컴퍼니 리미티드	Aadc/gdnf 폴리뉴클레오티드 및 이의 파킨슨병 치료에 있어서의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
US5158881A (en)	1987-11-17	1992-10-27	Brown University Research Foundation	Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en)	1987-11-17	1992-04-21	Brown University Research Foundation	Neurological therapy devices
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
CA2006596C (en)	1988-12-22	2000-09-05	Rika Ishikawa	Chemically-modified g-csf
WO1990014363A1 (en)	1989-05-19	1990-11-29	Amgen Inc.	Metalloproteinase inhibitor
US5229500A (en)	1989-08-30	1993-07-20	Regeneron Pharmaceuticals, Inc.	Brain derived neurotrophic factor
CA1332433C (en)	1989-09-29	1994-10-11	Robert L. Sutherland	Ski structure and binding therefor
DE69034258D1 (de)	1989-10-16	2008-09-18	Amgen Inc	Stamzellfaktor
US5272071A (en)	1989-12-22	1993-12-21	Applied Research Systems Ars Holding N.V.	Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010470A1 (en)	1990-01-08	1991-07-25	Brown University Research Foundation	Devices and methods for enhanced delivery of active factors
US5202428A (en)	1990-06-20	1993-04-13	The Salk Institute For Biological Studies	DNA encoding neurotropic growth factor
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
ATE275197T1 (de)	1991-09-20	2004-09-15	Amgen Inc	Glial neurotrophe faktor
AU1443095A (en)	1993-12-22	1995-07-10	University Of Medicine And Dentistry Of New Jersey	Novel nucleic acid sequences isolated from glial cells
FR2717824B1 (fr)	1994-03-25	1996-04-26	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
US5733875A (en) *	1994-11-15	1998-03-31	Amgen Inc.	Methods of using GDNF as a neuroprotective agent
US5739307A (en) *	1995-08-28	1998-04-14	Washington University	Polynucleotide encoding neurturin neurotrophic factor
US5731284A (en) *	1995-09-28	1998-03-24	Amgen Inc.	Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en)	1995-09-28	2001-02-06	Amgen Inc.	Truncated glial cell line-derived neurotrophic factor
US5641749A (en) *	1995-11-29	1997-06-24	Amgen Inc.	Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) *	1995-11-29	1997-06-24	Amgen Inc.	Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) *	1996-02-23	1999-07-27	Amgen Inc.	Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) *	1996-02-23	1998-11-17	Amgen Inc.	Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) *	1996-03-19	1998-04-21	Amgen Inc.	Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product

1995
- 1995-09-28 US US08/535,681 patent/US6184200B1/en not_active Expired - Lifetime
1996
- 1996-09-16 CA CA002232749A patent/CA2232749C/en not_active Expired - Fee Related
- 1996-09-16 DK DK96931618T patent/DK0920448T3/da active
- 1996-09-16 EP EP96931618A patent/EP0920448B1/en not_active Expired - Lifetime
- 1996-09-16 NZ NZ318697A patent/NZ318697A/en not_active IP Right Cessation
- 1996-09-16 EA EA199800301A patent/EA001204B1/ru not_active IP Right Cessation
- 1996-09-16 SK SK389-98A patent/SK288094B6/sk not_active IP Right Cessation
- 1996-09-16 AT AT96931618T patent/ATE314389T1/de active
- 1996-09-16 KR KR1019980702293A patent/KR100334739B1/ko not_active IP Right Cessation
- 1996-09-16 UA UA98031545A patent/UA66339C2/uk unknown
- 1996-09-16 JP JP51349497A patent/JP4153036B2/ja not_active Expired - Fee Related
- 1996-09-16 ES ES96931618T patent/ES2255713T3/es not_active Expired - Lifetime
- 1996-09-16 SI SI9630726T patent/SI0920448T1/sl unknown
- 1996-09-16 AU AU70746/96A patent/AU707528B2/en not_active Ceased
- 1996-09-16 WO PCT/US1996/014915 patent/WO1997011964A1/en active Application Filing
- 1996-09-16 IL IL12376196A patent/IL123761A/en not_active IP Right Cessation
- 1996-09-16 DE DE69635675T patent/DE69635675T2/de not_active Expired - Lifetime
- 1996-09-16 CZ CZ0088298A patent/CZ297326B6/cs not_active IP Right Cessation
- 1996-09-16 HU HU9802262A patent/HU226220B1/hu not_active IP Right Cessation
- 1996-09-16 CN CNB961972335A patent/CN1283659C/zh not_active Expired - Fee Related
- 1996-09-16 IL IL14401896A patent/IL144018A0/xx unknown
- 1996-09-16 IL IL14448896A patent/IL144488A0/xx active IP Right Grant
- 1996-09-26 ZA ZA968087A patent/ZA968087B/xx unknown
- 1996-09-26 TW TW085111819A patent/TW570926B/zh not_active IP Right Cessation
1998
- 1998-03-23 MX MX9802278A patent/MX9802278A/es active IP Right Grant
- 1998-03-30 NO NO19981430A patent/NO322521B1/no not_active IP Right Cessation
1999
- 1999-12-09 HK HK99105788A patent/HK1021823A1/xx not_active IP Right Cessation
2001
- 2001-06-26 IL IL144018A patent/IL144018A/en not_active IP Right Cessation
- 2001-07-23 IL IL144488A patent/IL144488A/en not_active IP Right Cessation
2004
- 2004-01-07 US US10/753,592 patent/US7390781B2/en not_active Expired - Fee Related
- 2004-05-25 US US10/853,930 patent/US20040214776A1/en not_active Abandoned
- 2004-05-26 US US10/855,820 patent/US7611865B2/en not_active Expired - Fee Related
2007
- 2007-09-05 JP JP2007229870A patent/JP4909843B2/ja not_active Expired - Fee Related
2010
- 2010-06-21 JP JP2010140665A patent/JP5241037B2/ja not_active Expired - Fee Related
2011
- 2011-06-23 US US13/167,419 patent/US20110251267A1/en not_active Abandoned
2012
- 2012-02-27 IL IL218336A patent/IL218336A0/en unknown

Also Published As

Publication number	Publication date
ZA968087B (en)	1997-06-12
SK288094B6 (sk)	2013-07-02
JPH11512709A (ja)	1999-11-02
IL123761A (en)	2005-12-18
HK1021823A1 (en)	2000-07-07
HUP9802262A3 (en)	2001-01-29
MX9802278A (es)	1998-08-30
CN1283659C (zh)	2006-11-08
CN1197461A (zh)	1998-10-28
DE69635675D1 (de)	2006-02-02
AU7074696A (en)	1997-04-17
US20040127419A1 (en)	2004-07-01
SI0920448T1 (sl)	2006-04-30
EA199800301A1 (ru)	1998-10-29
IL144018A0 (en)	2002-04-21
HUP9802262A2 (hu)	1999-01-28
NZ318697A (en)	1999-09-29
JP4153036B2 (ja)	2008-09-17
KR100334739B1 (ko)	2002-09-17
CZ88298A3 (cs)	1999-02-17
AU707528B2 (en)	1999-07-15
SK38998A3 (en)	1999-07-12
EA001204B1 (ru)	2000-12-25
DK0920448T3 (da)	2006-04-10
ES2255713T3 (es)	2006-07-01
IL144488A0 (en)	2002-05-23
KR19990063825A (ko)	1999-07-26
EP0920448A1 (en)	1999-06-09
NO981430L (no)	1998-03-30
IL218336A0 (en)	2012-04-30
CA2232749C (en)	2003-03-25
CZ297326B6 (cs)	2006-11-15
CA2232749A1 (en)	1997-04-03
TW570926B (en)	2004-01-11
HU226220B1 (hu)	2008-06-30
NO322521B1 (no)	2006-10-16
JP5241037B2 (ja)	2013-07-17
EP0920448B1 (en)	2005-12-28
WO1997011964A1 (en)	1997-04-03
DE69635675T2 (de)	2006-07-06
US7390781B2 (en)	2008-06-24
US20040254114A1 (en)	2004-12-16
US6184200B1 (en)	2001-02-06
JP2010279360A (ja)	2010-12-16
IL144018A (en)	2012-04-30
ATE314389T1 (de)	2006-01-15
IL144488A (en)	2006-12-31
IL123761A0 (en)	1998-10-30
US20040214776A1 (en)	2004-10-28
NO981430D0 (no)	1998-03-30
US20110251267A1 (en)	2011-10-13
JP2008067699A (ja)	2008-03-27
US7611865B2 (en)	2009-11-03
JP4909843B2 (ja)	2012-04-04

Publication	Publication Date	Title
UA66339C2 (uk)	2004-05-17	Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування
UA73719C2 (en)	2005-09-15	Human interleukin-2 mutant which activates preferably t-cells as compared with natural killer cells, pharmaceutical composition, polynucleotide, vector, procariotic cell, a method for the stimulation of immune system
CZ288890B6 (cs)	2001-09-12	MGDF polypeptid pro stimulaci růstu a diferenciaci megakaryocytů
EP0909316B1 (en)	2006-08-30	Glial cell line-derived neurotrophic factor receptor
KR20050021502A (ko)	2005-03-07	인터페론-β를 이용한 신부전증의 치료법
JP2002536018A (ja)	2002-10-29	グリコシル化レプチン組成物および関連する方法
KR20180042432A (ko)	2018-04-25	신규 인간 혈청 알부민 변이체
CA2291608C (en)	2004-04-13	Neurotrophic factor receptors
JP2001527402A (ja)	2001-12-25	Ｎｇｆ変異体
KR20050059195A (ko)	2005-06-17	인터페론-β를 이용한 만성 염증성 탈수초성다발성신경병증의 치료
US7138251B1 (en)	2006-11-21	Polynucleotides encoding a neurotrophic factor receptor
WO2005058951A1 (ja)	2005-06-30	糖鎖欠損型肝細胞増殖因子
WO1999003999A1 (en)	1999-01-28	Methods and compositions for inhibiting the proinflammatory response
KR100409099B1 (ko)	2003-12-11	신경 손상 치료 기구